These aforementioned findings indicated the potential value of IGF2BP3 as a biomarker for predicting CRC and as a favorable survival outcome prognostic factor, consistent with previous findings [8, 9]. This evidence concerns the gene IGF2BP3 and colorectal carcinoma.